menu search

MDNA / Medicenna Therapeutics: Treating Cancer With Immunomodulators

Medicenna Therapeutics: Treating Cancer With Immunomodulators
Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for treating rGBM, MDNA55, has shown promising efficacy and safety data in its recently concluded phase II trial. Read More
Posted: Nov 12 2021, 21:34
Author Name: Seeking Alpha
Views: 110572

MDNA News  

Why Is Medicenna Therapeutics (MDNA) Stock Down Today?

By InvestorPlace
October 30, 2023

Why Is Medicenna Therapeutics (MDNA) Stock Down Today?

Medicenna Therapeutics (NASDAQ: MDNA ) stock is falling on Monday after the immunotherapy company alerted investors to a delisting notice. Medicenna more_horizontal

Medicenna: Multiple Catalysts Ahead In 2023

By Seeking Alpha
February 28, 2023

Medicenna: Multiple Catalysts Ahead In 2023

Medicenna is testing MDNA11, an IL-2 superkine, with potential in various cancer types, in a phase 1/2 trial called ABILITY. A February 2023 update te more_horizontal

Medicenna Therapeutics Corp. (MDNA) Q3 2023 Earnings Call Transcript

By Seeking Alpha
February 7, 2023

Medicenna Therapeutics Corp. (MDNA) Q3 2023 Earnings Call Transcript

Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q3 2023 Earnings Conference Call February 7, 2023 8:30 AM ET Company Participants Dan Ferry - Investor Rel more_horizontal

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call Transcript

By Seeking Alpha
June 22, 2022

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call Transcript

Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Adv more_horizontal

Medicenna Therapeutics: Treating Cancer With Immunomodulators

By Seeking Alpha
November 12, 2021

Medicenna Therapeutics: Treating Cancer With Immunomodulators

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre more_horizontal

Medicenna Therapeutics: Treating Cancer With Immunomodulators

By Seeking Alpha
November 12, 2021

Medicenna Therapeutics: Treating Cancer With Immunomodulators

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre more_horizontal

Medicenna Therapeutics: Treating Cancer With Immunomodulators

By Seeking Alpha
November 12, 2021

Medicenna Therapeutics: Treating Cancer With Immunomodulators

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre more_horizontal


Search within

Pages Search Results: